20/20 Biolabs, Inc.
AIDX
$0.60
$0.011.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -34.35% | 28.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -34.35% | 28.78% | |||
| Cost of Revenue | -28.78% | 49.47% | |||
| Gross Profit | -51.76% | -10.13% | |||
| SG&A Expenses | 48.22% | 12.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.82% | 19.12% | |||
| Operating Income | -58.13% | -14.07% | |||
| Income Before Tax | -66.29% | -58.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -66.29% | -58.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -66.29% | -58.43% | |||
| EBIT | -58.13% | -14.07% | |||
| EBITDA | -59.67% | -14.58% | |||
| EPS Basic | 19.69% | -50.18% | |||
| Normalized Basic EPS | 17.59% | -50.19% | |||
| EPS Diluted | 20.07% | -50.89% | |||
| Normalized Diluted EPS | 17.59% | -50.19% | |||
| Average Basic Shares Outstanding | 101.92% | 5.48% | |||
| Average Diluted Shares Outstanding | 101.92% | 5.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||